AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3581636 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo‐dur Sprinkle
Number of subjects: 15
Study 29661642 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 688
Study 29661642 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 688
Study 27149496 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT) during the temporary stoma period
Number of subjects: 56
Study 27149496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BFT)
Number of subjects: 56
Study 27149496 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT)
Number of subjects: 56
Study 24275838 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan-amlodipine (80/5 mg, then 160/10 mg)
Number of subjects: 373
Study 24275838 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-amlodipine (50/5 mg, then 100/10 mg)
Number of subjects: 373
Study 22554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nasolabial flap
Number of subjects: 20
Study 22554695 — intervention group
Group type: COMPARATOR
Intervention: Platysma myocutaneous muscle flap
Number of subjects: 20
Study 20715088 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ethmoidectomy, middle meatus antrostomy, and excision of the cysts (group A)
Number of subjects: 80
Study 20715088 — intervention group
Group type: COMPARATOR
Intervention: Ethmoidectomy and antrostomy without cyst detachment (group B)
Number of subjects: 80
Study 18280619 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formula (EHF)
Number of subjects: 20
Study 18280619 — intervention group
Group type: COMPARATOR
Intervention: Partially hydrolysed formula (PHF)
Number of subjects: 20
Study 18280619 — intervention group
Group type: COMPARATOR
Intervention: Intact protein formula (IPF)
Number of subjects: 20
Study 15902987 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cycling exercise (INT) consisting of seven 2 min work intervals at 90% VO2max, followed by 3 min of relief at 30% VO2max.
Number of subjects: 12
Study 15902987 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling exercise (CON) consisting of 30 to 32 min at 65% VO2max.
Number of subjects: 12
Study 12133124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual benzodiazepine taper combined with cognitive-behavioural therapy
Number of subjects: 76
Study 12133124 — intervention group
Group type: COMPARATOR
Intervention: Standard withdrawal treatment
Number of subjects: 76
Study 10224354 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25 (humanized monoclonal antibody against IgE)
Number of subjects: 0
Study 10224354 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 0
Study 7776406 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 29
Study 7776406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1691367 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg felodipine extended-release (ER) tablets
Number of subjects: 12
Study 1691367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 523172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg FK (synthetic enkephalin analogue) intramuscularly
Number of subjects: 0
Study 523172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg FK intramuscularly
Number of subjects: 0
Study 523172 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg FK intramuscularly
Number of subjects: 0
Study 523172 — intervention group
Group type: COMPARATOR
Intervention: 50 mg betazole (placebo)
Number of subjects: 0
Study 30869570 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent enrollment
Number of subjects: 56
Study 27794193 — intervention group
Group type: EXPERIMENTAL
Intervention: Water sweetened with saccharin (5 mg/kg body weight)
Number of subjects: 40
Study 27794193 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study 27794193 — intervention group
Group type: EXPERIMENTAL
Intervention: Water sweetened with saccharin
Number of subjects: 40
Study 25455437 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank ergometry (ACE)
Number of subjects: 9
Study 25455437 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometry (CE)
Number of subjects: 9
Study 25455437 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking (TM)
Number of subjects: 9
Study 23636153 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based education intervention
Number of subjects: 203
Study 23636153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study 22143220 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination education
Number of subjects: 125
Study 22143220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 125
Study 19186901 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving voice (objectively fair procedures)
Number of subjects: 385
Study 19186901 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice x Identity Violation interaction
Number of subjects: 385
Study 17076823 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg cortisol
Number of subjects: 35
Study 17076823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15598481 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 135 mg (<or=5 doses/d)
Number of subjects: 123
Study 15598481 — intervention group
Group type: COMPARATOR
Intervention: Loperamide 4 mg (loading dose) followed by 2 mg (<or=8 mg/d) after each loose stool
Number of subjects: 123
Study 11386493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 91
Study 11386493 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual
Number of subjects: 91
Study 11386493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and self-help manual
Number of subjects: 91
Study 11386493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 10809268 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with naloxone
Number of subjects: 25
Study 10809268 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia with naloxone
Number of subjects: 25
Study 10809268 — intervention group
Group type: COMPARATOR
Intervention: Both anesthetics with naloxone
Number of subjects: 25
Study 8820889 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, intermittent contractions (IC)
Number of subjects: 9
Study 8820889 — intervention group
Group type: EXPERIMENTAL
Intervention: Long, continuous contractions (CC)
Number of subjects: 9
Study 8820889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 1317343 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg immune serum globulin
Number of subjects: 10
Study 1317343 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg immune serum globulin
Number of subjects: 10
Study 1317343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (1 microgram/dose)
Number of subjects: 10
Study 1317343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (0.5 micrograms/dose)
Number of subjects: 10
Study 1317343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (0.25 micrograms/dose)
Number of subjects: 10
Study 3934956 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 0
Study 3934956 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 0
Study 29465549 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic rehabilitation program composed of aerobic and resisted exercises, performed for 12 weeks, in 3 weekly meetings of 60 minutes each.
Number of subjects: 0
Study 26982602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin-Duloxetine Combination
Number of subjects: 41
Study 26982602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 41
Study 26982602 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41
Study 26982602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25279525 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (Class II subdivision)
Number of subjects: 90
Study 25279525 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (Class II)
Number of subjects: 90
Study 25279525 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Class I)
Number of subjects: 90
Study 22865033 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline alternating with 5% dextrose at rate of 175 ml/h
Number of subjects: 250
Study 22865033 — intervention group
Group type: COMPARATOR
Intervention: Normal saline alone
Number of subjects: 250
Study 20578975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball emitting broadband sound
Number of subjects: 0
Study 20578975 — intervention group
Group type: COMPARATOR
Intervention: Non-sound group
Number of subjects: 0
Study 20578975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18051011 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental technique (four oblique layers) with total-etch adhesive (Single Bond)
Number of subjects: 60
Study 18051011 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite as liner and bulk technique
Number of subjects: 60
Study 18051011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk technique
Number of subjects: 60
Study 18051011 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cone technique
Number of subjects: 60
Study 18051011 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental technique with self-etch adhesive (AdheSE)
Number of subjects: 60
Study 18051011 — intervention group
Group type: COMPARATOR
Intervention: Total-etch adhesive (Single Bond) with incremental technique
Number of subjects: 60
Study 15632026 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke treadmill score (DTS)
Number of subjects: 997
Study 15632026 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide angiography with ejection fraction (RNA-EF)
Number of subjects: 997
Study 15632026 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT perfusion imaging
Number of subjects: 997
Study 12184476 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 568
Study 12184476 — intervention group
Group type: COMPARATOR
Intervention: Left-handers
Number of subjects: 568
Study 12184476 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed males
Number of subjects: 568
Study 12184476 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 568
Study 10639704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery (25 women)
Number of subjects: 25
Study 10639704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery (multiparae)
Number of subjects: 25
Study 10639704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery (primiparae)
Number of subjects: 25
Study 10639704 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 nulliparous women)
Number of subjects: 25
Study 7846539 — intervention group
Group type: COMPARATOR
Intervention: etoposide/cisplatin (VP)
Number of subjects: 171
Study 7846539 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide/ifosfamide/cisplatin (VIP)
Number of subjects: 171
Study 7846539 — intervention group
Group type: EXPERIMENTAL
Intervention: daily oral etoposide/ifosfamide/cisplatin
Number of subjects: 171
Study 2185963 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 65
Study 2185963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 65
Study 2185963 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Pirprofen
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 65
Study 2185963 — intervention group
Group type: COMPARATOR
Intervention: Suprofen
Number of subjects: 65
Study 30580454 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin (5 mg/day)
Number of subjects: 44
Study 30580454 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 29083936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (50 mg losartan/12.5 mg HCTZ)
Number of subjects: 201
Study 29083936 — intervention group
Group type: COMPARATOR
Intervention: High-dose therapy (100 mg losartan)
Number of subjects: 201
Study 27538188 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 10154
Study 24494695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior mental health specialty treatment
Number of subjects: 107
Study 24494695 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (every one-unit decrease)
Number of subjects: 107
Study 22115823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 89
Study 22115823 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 5 mg
Number of subjects: 89
Study 19562362 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 80
Study 19562362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 18391460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) and iron for 8 weeks
Number of subjects: 16
Study 18391460 — intervention group
Group type: COMPARATOR
Intervention: Iron only for 8 weeks (Control)
Number of subjects: 16
Study 16317534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/daily) for a maximum of 2 weeks
Number of subjects: 64
Study 16317534 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (diclofenac 100 mg/daily plus aescin 80 mg/daily)
Number of subjects: 64
Study 16317534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 12883407 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (target-controlled infusion at concentrations of 2, 4, or 6 microg/ml)
Number of subjects: 30
Study 12883407 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (increasing concentrations from 0 to 7 ng/ml)
Number of subjects: 30
Study 10546920 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 18
Study 10546920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 18
Study 10546920 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 18
Study 8914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (placebo, low 7 mg/day, medium 14 mg/day, high 21 mg/day)
Number of subjects: 0
Study 8914115 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 0
Study 8914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (all doses)
Number of subjects: 0
Study 1711261 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 500 ml hydroxyethylstarch 6% 0.62
Number of subjects: 207
Study 1711261 — intervention group
Group type: COMPARATOR
Intervention: 3 X 5000 IE unfractionated heparin
Number of subjects: 207
Study 6406947 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutonidin (F) 2 mg/day
Number of subjects: 30
Study 6406947 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (C) 0.3 mg/day
Number of subjects: 30
Study 30629889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 30629889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30629889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (completers)
Number of subjects: 15
Study 30629889 — intervention group
Group type: COMPARATOR
Intervention: Placebo + non-completers
Number of subjects: 15
Study 30629889 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance group
Number of subjects: 15
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 1
Number of subjects: 36
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 30μg in cohort 1
Number of subjects: 36
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 2
Number of subjects: 36
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 3
Number of subjects: 36
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 treatment at dose levels from 150μg to 900μg
Number of subjects: 36
Study 29191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 treatment
Number of subjects: 36
Study 29191561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26577402 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban HIV risk‐reduction intervention
Number of subjects: 535
Study 26577402 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 535
Study 25126888 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy program Vernetzte www.Welten
Number of subjects: 2303
Study 25126888 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular class)
Number of subjects: 2303
Study 21903027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus omega-3
Number of subjects: 105
Study 21903027 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 105
Study 18670195 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 13
Number of subjects: 71
Study 18670195 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 14
Number of subjects: 71
Study 18670195 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 17
Number of subjects: 71
Study 17451570 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict gluten-free diet with good clinical response
Number of subjects: 31
Study 15154363 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid addition with standard therapy
Number of subjects: 0
Study 12235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Number of subjects: 102
Study 12235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic resistance training
Number of subjects: 102
Study 12235596 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 9678528 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum free IGF-I
Number of subjects: 218
Study 9678528 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IGF-I
Number of subjects: 218
Study 9678528 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total IGF-I
Number of subjects: 218
Study 7516019 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (5 mg i.v. infusion)
Number of subjects: 10
Study 7516019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg oral daily for 5 days)
Number of subjects: 10
Study 7516019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2683568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root (Zingiber officinale)
Number of subjects: 0
Study 2683568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 0
Study 2683568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29554385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous aflibercept injection (IAI) with a fixed bimonthly regimen for the first 2 years, followed by routine clinical practice regimen in the third year.
Number of subjects: 18
Study 27402004 — intervention group
Group type: EXPERIMENTAL
Intervention: CFE + CA
Number of subjects: 155
Study 27402004 — intervention group
Group type: COMPARATOR
Intervention: CFE
Number of subjects: 155
Study 26083958 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (Chantix)
Number of subjects: 0
Study 26083958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22999261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg twice daily; PO)
Number of subjects: 50
Study 22999261 — intervention group
Group type: COMPARATOR
Intervention: Metformin (750 mg twice daily; PO)
Number of subjects: 50
Study 22999261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 21371770 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lipoic acid (LA)
Number of subjects: 102
Study 21371770 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg α-tocopherol
Number of subjects: 102
Study 21371770 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg α-tocopherol + 600 mg lipoic acid (LA)
Number of subjects: 102
Study 21371770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18315636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational technique with cuff partially inflated
Number of subjects: 168
Study 18315636 — intervention group
Group type: COMPARATOR
Intervention: Lateral technique with cuff partially inflated
Number of subjects: 168
Study 18315636 — intervention group
Group type: COMPARATOR
Intervention: Standard Brain technique
Number of subjects: 168
Study 16223655 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural equation modeling (SEM) technique
Number of subjects: 0
Study 16223655 — intervention group
Group type: EXPERIMENTAL
Intervention: Then test
Number of subjects: 0
Study 16223655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized approach
Number of subjects: 0
Study 12057717 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) at a dose of 1.8 g/day orally for 5-6 weeks; 3 g/day for massively obese subjects
Number of subjects: 37
Study 12057717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10079438 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with nonperforating deep sclerectomy (P-DS)
Number of subjects: 60